ClinicalTrials.gg
Not yet recruitingNCT07363265Updated Jan 23, 2026

Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease

A Phase 2 interventional study of LP-005 Injection in Complement-mediated Renal Diseases, sponsored by Longbio Pharma. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Longbio Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a multicenter, open-label, proof-of-concept, phase Ⅱ adaptive basket clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of LP-005 Injection as add-on therapy to standard treatment in patients with complement-mediated renal diseases.

02

Conditions studied

  • Complement-mediated Renal Diseases
03

In context

Lead sponsor

Longbio Pharma is the lead sponsor of 13 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 18 to 65 years at screening.
  2. Body weight of ≥ 40 kg and a (BMI) within the range of 15 to 35 kg/m\^2 (inclusive).
  3. Patients with complement-mediated renal disease.
  4. Females and males of (including the participants' partners) must agree to use effective measures during the trial and for 3 months after the trial ends.
  5. Willing to participate in this clinical trial and voluntarily sign the form; additionally, be assessed by the investigator as being able to fully understand and comply with all planned study procedures and other requirements.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating female.
  2. History of meningococcal infection.
  3. Active, uncontrolled acute, chronic, or recurrent infection within 4 weeks prior to screening.
  4. Other severe, poorly controlled comorbidities within 3 months prior to screening.
  5. Patients with known to any component of LP-005 or a history of atopic diathesis.
  6. History of within 5 years prior to screening, except for resected cutaneous basal cell carcinoma, resected cutaneous squamous cell carcinoma, and completely resected carcinoma in situ without evidence of local recurrence or (e.g., cervical carcinoma in situ or breast carcinoma in situ).
  7. Prior use of any complement inhibitor within 3 months prior to screening or 5 half-lives of the drug, whichever is longer.
  8. Participation in another clinical trial with administration of drug or medical device within 4 weeks prior to screening or 5 half-lives of the administered product, whichever applies.
  9. Any condition that, in the investigator's judgment, may impede study participation, pose a safety risk to the participant, or confound the interpretation of study results.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    LP-005

    Patients with complement-mediated renal diseases will be treated with predefined dose of LP-005 (1200 mg or 1500 mg).

    Biological: LP-005 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in 24-hour urinary protein-to-creatinine ratio (UPCR) in Basket 1 cohort

    Time frame: Week 24

  2. Proportion of patients with a ≥25% reduction in serum creatinine (SCr) from baseline in Basket 2 cohort

    Time frame: Week 24

  3. Proportion of patients without dialysis requirement in Basket 3 cohort

    Time frame: Week 24

Secondary outcomes

  1. Change from baseline in serum creatinine (SCr)

    Time frame: Up to approximately 64 weeks

  2. Change from baseline in estimated glomerular filtration rate (eGFR)

    Time frame: Up to approximately 64 weeks

  3. Incidence of AEs

    Time frame: Up to approximately 64 weeks

  4. Serum concentrations of LP-005

    Time frame: Up to approximately 64 weeks

  5. Number of patients with anti-drug antibodies (ADA)

    Time frame: Up to approximately 64 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Aug 2028, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 23, 2026
StartEst.
Feb 2, 2026
Primary completionEst.
Aug 2, 2028
CompletionEst.
May 2, 2029
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07363265
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Feb 2, 2026 (estimated)
Primary completion
Aug 2, 2028 (estimated)
Completion
May 2, 2029 (estimated)
Last update
Jan 23, 2026

Study contacts

Jie Yang
Contact
yangj@longbiopharma.com
+86 021-58372390
Minghui Zhao
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-005

Start the discussion